series-b
Stage
1
Investors
About
BridGene Biosciences is a biotechnology company that discovers and develops small molecule drugs for traditionally "hard-to-drug" targets, utilizing its proprietary IMTAC™ chemoproteomic platform to identify novel binding sites and drug candidates for high-value targets in oncology and autoimmune diseases.
Explore BridGene Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.